Skip to main content

For questions about financial assistance, call 1-844-DUPIXENT, option 1 or
click to learn more  

DU MORE TO HELP EASE EoE IN CHILDREN

RESULTS WITH DUPIXENT IN CHILDREN
(1‑11 YEARS WEIGHING AT LEAST 33 lbs)

The Only FDA-Approved
Treatment OF ITS KIND For
Children With EoE

If your child is having trouble with food, it's time to learn how
DUPIXENT may be able to help.

EoE in Children: Results
with Dupixent

DUPIXENT REDUCED

Inflammation in the
esophagus

CAREGIVERS OBSERVED THAT CHILDREN EXPERIENCED

FEWER DAYS WITH EoE
SIGNS
AND SYMPTOMS

AS EARLY AS 4 MONTHS AND AT 1 YEAR*

VISIBLE IMPROVEMENTS
IN THE ESOPHAGUS

WERE SEEN IN CHILDREN

DUPIXENT was studied in 61 patients ages 1 to 11 years old (≥33 lbs) with EoE in a two-part study.

*As measured by the Pediatric EoE Sign/Symptom Questionnaire-Caregiver
(PESQ-C).

The most common side effects
with EoE include:

  • Injection site reactions
  • Upper respiratory tract infections
  • Cold sores in your mouth or on your lips
  • Joint pain (arthralgia)

View the possible side effects of DUPIXENT in patients with eosinophilic esophagitis.

Have a productive
Conversation With
Your Doctor

Our goal is for you or your loved one to get the most out of your visit to the doctor. Fill out our personalized discussion guide to help yourself have a productive conversation during your next visit.

Find an EoE Specialist

Use the Healthgrades™ tool to easily find nearby
specialists with experience in treating patients suffering
from eosinophilic esophagitis (EoE).

Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.

Treating Children With
DUPIXENT

DUPIXENT is a biologic medicine given under the skin (subcutaneous injection). The
recommended dose for your child can depend on age and weight.

GET EMAIL UPDATES

Sign up to get more information to help you and your child, including helpful tools and
resources, in your inbox with DUPIXENT MyWay® email updates.